Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
11 Total results for product and free and sample content found
HBW Insight
Infographic: COVID-19 delivers an 8% sales growth injection to Germany's supplements market in the first half of the year, accelerating a long-term expansion.
Skipta
With the COVID-19 pandemic raging, verified HCPs are turning to Skipta more than ever to access clinically relevant information reaching beyond the crisis. Find out how other brand managers engaged these members using Skipta’s disease-specific micro-communities.
Topic Neurology Market Intelligence
Awareness, Thought leadership, Scrip
The annual “Scrip Asia 100”, the highly anticipated financial performance ranking of pharma companies headquartered in the APAC region, is coming soon. Don’t miss your opportunity to position yourself as a leader in APAC pharma with a sponsorship in this indispensable publication.
Awareness, Lead generation, Our products and ...
With deep Pharma industry and marketing expertise, we can help you to reach Pharma’s elusive decision makers with relevant high-impact and engaging content, so you can reach your business and revenue objectives.
Topic Market Intelligence
Awareness
To reach today’s Pharma decision makers, you must provide the right high-quality content to help them make educated purchasing decisions – and become loyal customers.
Scrip
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.
HBW Insight
An interactive timeline of HBW Insight's coverage of the blossoming European CBD market in 2019. The timeline covers the main events of the year beginning with the European Commission's decision to classify CBD as a novel food, and ending on the filing of the first application for a synthetic form of the cannabis-derived ingredient.
Scrip
Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.
Scrip
Access Asia Pharma Intelligence expertise and hear from Pharma journalists across Asia to reveal deep regional expertise with this sample of Scrip's Asia 100 Report.
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
